GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Generation Bio Co (NAS:GBIO) » Definitions » Beneish M-Score

GBIO (Generation Bio Co) Beneish M-Score : 3.21 (As of Dec. 14, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Generation Bio Co Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Warning Sign:

Beneish M-Score 3.21 higher than -1.78, which implies that the company might have manipulated its financial results.

The historical rank and industry rank for Generation Bio Co's Beneish M-Score or its related term are showing as below:

GBIO' s Beneish M-Score Range Over the Past 10 Years
Min: 3.21   Med: 6.15   Max: 9.08
Current: 3.21

During the past 6 years, the highest Beneish M-Score of Generation Bio Co was 9.08. The lowest was 3.21. And the median was 6.15.


Generation Bio Co Beneish M-Score Historical Data

The historical data trend for Generation Bio Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Generation Bio Co Beneish M-Score Chart

Generation Bio Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - - - -

Generation Bio Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 9.08 3.21

Competitive Comparison of Generation Bio Co's Beneish M-Score

For the Biotechnology subindustry, Generation Bio Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Generation Bio Co's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Generation Bio Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Generation Bio Co's Beneish M-Score falls into.



Generation Bio Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Generation Bio Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.5458+0.528 * 1+0.404 * 4.5159+0.892 * 6.1408+0.115 * 0.5362
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.1369+4.679 * 0.047756-0.327 * 1.6713
=3.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Total Receivables was $2.21 Mil.
Revenue was 7.554 + 4.091 + 4.059 + 2.878 = $18.58 Mil.
Gross Profit was 7.554 + 4.091 + 4.059 + 2.878 = $18.58 Mil.
Total Current Assets was $191.25 Mil.
Total Assets was $248.78 Mil.
Property, Plant and Equipment(Net PPE) was $37.23 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.08 Mil.
Selling, General, & Admin. Expense(SGA) was $42.50 Mil.
Total Current Liabilities was $30.17 Mil.
Long-Term Debt & Capital Lease Obligation was $82.98 Mil.
Net Income was -15.313 + -20.432 + -74.541 + -35.186 = $-145.47 Mil.
Non Operating Income was -1.169 + -1.497 + -56.93 + 0 = $-59.60 Mil.
Cash Flow from Operations was -19.547 + -21.535 + -31.697 + -24.978 = $-97.76 Mil.
Total Receivables was $0.66 Mil.
Revenue was 2.146 + 0.88 + 0 + 0 = $3.03 Mil.
Gross Profit was 2.146 + 0.88 + 0 + 0 = $3.03 Mil.
Total Current Assets was $297.81 Mil.
Total Assets was $381.49 Mil.
Property, Plant and Equipment(Net PPE) was $76.79 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.28 Mil.
Selling, General, & Admin. Expense(SGA) was $50.56 Mil.
Total Current Liabilities was $32.82 Mil.
Long-Term Debt & Capital Lease Obligation was $70.99 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.212 / 18.582) / (0.66 / 3.026)
=0.11904 / 0.21811
=0.5458

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(3.026 / 3.026) / (18.582 / 18.582)
=1 / 1
=1

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (191.254 + 37.23) / 248.784) / (1 - (297.809 + 76.79) / 381.492)
=0.081597 / 0.018069
=4.5159

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=18.582 / 3.026
=6.1408

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.284 / (5.284 + 76.79)) / (5.08 / (5.08 + 37.23))
=0.064381 / 0.120066
=0.5362

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(42.5 / 18.582) / (50.555 / 3.026)
=2.28716 / 16.706874
=0.1369

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((82.982 + 30.165) / 248.784) / ((70.993 + 32.819) / 381.492)
=0.4548 / 0.272121
=1.6713

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-145.472 - -59.596 - -97.757) / 248.784
=0.047756

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Generation Bio Co has a M-score of 3.21 signals that the company is likely to be a manipulator.


Generation Bio Co Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Generation Bio Co's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Generation Bio Co Business Description

Traded in Other Exchanges
N/A
Address
301 Binney Street, Cambridge, MA, USA, 02142
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Executives
Antoinette Paone officer: CHIEF OPERATING OFFICER C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Dannielle Appelhans director C/O RUBIUS THERAPEUTICS, INC., 399 BINNEY STREET, SUITE 300, CAMBRIDGE MA 02139
Rowland Charles A Jr director 3338 LANCASHIRE RD, FURLONG PA 18925
Donald William Nicholson director C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Anthony G. Quinn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPWY, STE. 250, AUSTIN TX 78746
Yalonda Howze officer: CHIEF LEGAL OFFICER C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Phillip Samayoa officer: CHIEF STRATEGY OFFICER C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Jason P Rhodes director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates X, L.p. 10 percent owner 400 TECHNOLOGY SQ., 10TH FLOOR, CAMBRIDGE MA 02139
Matthew Stanton officer: Chief Scientific Officer C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Douglas Kerr officer: Chief Development Officer C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Geoff Mcdonough director, 10 percent owner, officer: See Remarks C/O SURFACE ONCOLOGY, INC., 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Tracy Zimmermann officer: Chief Development Officer C/O GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142
Cooper Ronald Harold Wilfred director C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Mark D. Angelino officer: Chief Operating Officer GENERATION BIO CO., 301 BINNEY STREET, SUITE 401, CAMBRIDGE MA 02142